Masimo Reports Second Quarter 2007 Financi...(evelopment efforts and the Company's glo...)

Date:9/19/2007

evelopment efforts and the Company's global business expansion. Under the two class method for computing and reporting earnings per share, the Company reported second quarter 2007 net income attributable to common stockholders of $2.8 million or $0.13 per common share based on weighted average common shares outstanding of 20,732,014 as compared to $3.9 million or $0.19 per common share based on weighted average common shares outstanding of 20,301,629 for the second quarter 2006. For the quarter ended June 30, 2007, on a non-GAAP basis and adjusting only for the assumed conversion of preferred stock into common stock in connection with the Company's recently completed initial public offering, net income was $0.19 per common share based on weighted average common shares outstanding of 55,344,517 as compared to $0.25 per common share based on weighted average common shares outstanding of 54,914,132 in the prior year period.

Joe E. Kiani, Chairman and Chief Executive Officer of Masimo, said, "We are happy to report a record second quarter with solid product revenue growth and net income that exceeded expectations. These results reflect the clinical community's recognition of the benefits of our breakthrough read-through

motion pulse oximetry, our strong customer service, and continued commitment to innovation, as evidenced by our new Rainbow SET platform."

For the six month period ended June 30, 2007, Masimo's product revenues were $93.4 million, up 29% from $72.5 million in the same prior year period. Including royalty revenues, Masimo's total revenues were $122.6 million for the six month period ended June 30, 2007, up from $105.1 million in the prior year period. In the six month period ended June 30, 2007, Masimo shipped a record 56,200 Masimo SET and Masimo Rainbow SET pulse oximeter units, excluding handheld pulse oximeters, compared to 46,600 in the same prior year period.

Net income for the six month period ended June 30, 2007 was $19.7 m
'/>"/>

SOURCE Masimo Corporation Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening